Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00111475
Other study ID # 20000137
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 1, 2002
Est. completion date June 17, 2004

Study information

Verified date December 2019
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with ITP.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date June 17, 2004
Est. primary completion date June 17, 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosis of ITP according to American Society of Hematology (ASH) guidelines at least 3 months before enrollment

- Have completed at least 1 prior treatment for ITP

- Two (including day -2) of the 3 platelet counts taken during the screening and pre-treatment periods must have fulfilled the following:

- less than 30 x 10^9/L for those subjects not receiving any ITP therapy,

- less than 50 x 10^9/L for those subjects receiving any ITP therapy

- Eastern Cooperative Oncology Group performance status of 0 to 2

- Serum creatinine concentration = 2 mg/dL (= 176.8 µmol/L)

- Adequate liver function, as evidenced by a serum bilirubin = 1.5 times the laboratory normal range

- Hemoglobin greater than 10.0 g/dL

- Written informed consent

Exclusion Criteria:

- Considered a substantial risk for adverse outcomes because of a clinically important trend (as determined by the investigator) detected in the platelet counts during the screening period

- Any known history of bone marrow stem cell disorder

- Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization

- Documented diagnosis of arterial thrombosis (ie, stroke, transient ischemic attack, or myocardial infarction) in the previous year; history of venous thrombosis (ie, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy

- Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure [New York Heart Association (NYHA) greater than class II], uncontrolled hypertension [diastolic greater than 100 mmHg] or cardiac arrhythmia)

- Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker using oral contraceptives; hypercholesteremia (> 240 mg/dL); treatment for hypertension

- Known positive test for human immunodeficiency virus (HIV) infection or hepatitis C virus

- Received any treatment for ITP (except for a constant dose schedule of corticosteroids) within 4 weeks before the screening visit

- Received intravenous (IV) immunoglobulin (Ig) or WinRho within 2 weeks before the screening visit

- Received hematopoietic growth factors, including interleukin (IL)-11 (Neumega®) within 4 weeks before the screening visit

- Past or present participation in any study evaluating polyethylene glycol recombinant human magakaryopoiesis differentiating factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or related platelet product

- Received any alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study

- Received any monoclonal antibody (eg, rituximab) within 16 weeks before the screening visit or anticipated use during the time of the proposed study

- Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period

- Less than 2 months since major surgery (including laparoscopic splenectomy)

- Pregnant or breast feeding

- Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Romiplostim
Administered by subcutaneous injection
Placebo
Administered by subcutaneous injection

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

References & Publications (2)

Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19;355(16):1672-81. Erratum in: N Engl J Med. 2006 Nov 9;355(19):2054. — View Citation

Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
Primary Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported. Assessed on day 29 (Part A only), day 43 (Part B only), and day 78
Secondary Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10? cells/L.
Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Number of Participants With an Increase in Platelet Count of = 20 x 10? Cells/L Over Baseline in Part A Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders. After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)
Secondary Number of Participants With a Peak Platelet Count = 100 x 10? Cells/L in Part A Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders. After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Number of Participants With a Peak Platelet Count of > 450 x 10? Cells/L in Part A Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders. After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Peak Platelet Count After Each Dose in Part A Platelet count data after the use of rescue medication were not included. After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Change From Baseline in Peak Platelet Count After Each Dose in Part A Platelet count data after the use of rescue medication were not included. Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Time to Peak Platelet Count After Each Dose in Part A Platelet count data after the use of rescue medication were not included. After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Duration Within the Targeted Therapeutic Platelet Range In Part A Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and = 50 and = 450 × 10? cells/L.
Platelet count data after the use of rescue medication were not included.
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Secondary Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10? cells/L and less than or equal to 450 x 10? cells/L.
Platelet count data after use of rescue medication were not included in the analysis.
Day 1 to day 78
Secondary Percentage of Participants With an Increase in Platelet Count of = 20 x 10? Cells/L Over Baseline in Part B Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders. Day 1 to day 78
Secondary Percentage of Participants With a Peak Platelet Count of = 100 x 10? Cells/L in Part B Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders. Day 1 to day 78
Secondary Percentage of Participants With a Peak Platelet Count of > 450 x 10? Cells/L in Part B Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders. Day 1 to day 78
Secondary Percentage of Participants With a Peak Platelet Count of > 500 x 10? Cells/L in Part B Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders. Day 1 to day 78
Secondary Peak Platelet Count in Part B Platelet count data after administration of rescue medication were not included in the analysis. Day 1 to day 78
Secondary Change From Baseline in Peak Platelet Count in Part B Platelet count data after administration of rescue medication were not included in the analysis. Baseline and day 1 to day 78
Secondary Time to Peak Platelet Count in Part B Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method. Day 1 to day 78
Secondary Duration Within the Targeted Therapeutic Platelet Range in Part B Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10? cells/L and less than or equal to 450 × 10? cells/L.
Platelet count data after administration of rescue medication were not included in the analysis.
Day 1 to day 78
See also
  Status Clinical Trial Phase
Completed NCT05220878 - Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP Phase 3
Completed NCT00451594 - High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Phase 3
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Recruiting NCT03465020 - Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Completed NCT00603642 - P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Phase 3
Completed NCT01143038 - Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim Phase 2
Not yet recruiting NCT04128358 - Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? N/A
Completed NCT00128882 - Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Completed NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Phase 4
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00625443 - Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Phase 2
Completed NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Phase 2
Completed NCT00454857 - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) N/A
Completed NCT00102323 - AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Phase 3
Completed NCT05492409 - Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients Phase 3
Terminated NCT01433978 - A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Phase 3
Withdrawn NCT01443351 - Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Completed NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Phase 3